NeuroPace to Present at the 2022 RBC Capital Markets Global Healthcare Conference
MOUNTAIN VIEW, Calif., May 13, 2022 – NeuroPace, a medical device company focused on epilepsy treatment, will present at the 2022 RBC Capital Markets Global Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MOUNTAIN VIEW, Calif., May 13, 2022 – NeuroPace, a medical device company focused on epilepsy treatment, will present at the 2022 RBC Capital Markets Global Healthcare Conference. CEO Mike Favet’s presentation is set for May 17 at 9:30 a.m. ET. A live webcast and archived recording will be accessible on the company’s website for 90 days. NeuroPace’s innovative RNS System offers personalized, real-time treatment for drug-resistant epilepsy, aiming to enhance care standards and improve outcomes for patients with various brain disorders.
Details
News Market Reaction – NPCE
The recorded move for NPCE in the trading session of this news was -1.76%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will be participating in the upcoming 2022 RBC Capital Markets Global Healthcare Conference. Mike Favet, CEO, is scheduled to present on Tuesday, May 17 at 9:30 a.m. Eastern Time. A live webcast of this event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://investors.neuropace.com. The webcasts will be archived and available for replay for at least 90 days after the event.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients suffering from drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Investor Contact:
Gilmartin Group
Matt Bacso, CFA
investors@neuropace.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.